A Randomised, Double-Blind, Dose-Escalation Phase I Study in Healthy Adults to Assess the Safety, Tolerability and Immunogenicity of Glycovax-002, a Novel Vaccine Candidate Against COVID-19
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Glycovax-002 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Glycovax Pharma
Most Recent Events
- 24 Sep 2024 Planned End Date changed from 1 Aug 2024 to 31 Dec 2024.
- 19 Mar 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Apr 2024.
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.